- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07927738
Clinical Efficacy of Jing Si Herbal Tea Liquid Packet to Treat Patients With Interstitial Cystitis/Bladder Pain Syndrome
Jing Si Herbal Tea Liquid Packet Combined Bladder Treatment or Only Bladder Treatment, and to Evaluate the Effect of the Jing Si Herbal Tea Liquid Packet Intervention of IC/BPS
Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of unknown etiology, with clinical characteristics of bladder pain, frequency, urgency, and nocturia. There has been no effective and durable medication to cure this disease. Current research has revealed that chronic bladder wall inflammation and bladder mucosal denudation are the fundamental pathology for clinical symptoms. Using Jing Si Herbal Tea liquid packets may have a therapeutic effect in patients with refractory IC/BPS.
Aim: To investigate the effect of Jing Si Herbal Tea liquid packet intervention added to urological therapy for patients with refractory IC/BPS.
Materials and Methods: This study will enroll patients with IC/BPS who are refractory to various conventional treatments after cystoscopic hydrodistention, antimuscarinic, and painkiller treatments. These patients plan to receive further intravesical IC therapy, such as intravesical hyaluronic acid (HA) instillation, intravesical botulinum toxin A (Botox) injection, intravesical platelet-rich plasma (PRP) injection, or low-energy shock wave (LESW) therapy. The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also assessed at baseline and at 4, 12, and 20 weeks after treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment.
Assessment: The patients will be investigated using the voiding diary (for frequency of nocturia episodes per day), ICSI, IC problem index (ICPI), Numerical Rating Scale (NRS) of pain, patient perception of bladder condition (PPBC), global response assessment (GRA), maximal flow rate (Qmax), voided volume (Vol), and post-void residual urine (PVR) volume measurement at baseline and after treatment. Urine samples will also be obtained for determination of urinary biomarkers at baseline and after different therapies.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of unknown etiology, with clinical characteristics of bladder pain, frequency, urgency, and nocturia. There has been no effective and durable medication to cure this disease. Patients with IC/BPS have increased anxiety, depression, loss of social relationships, and a high suicide rate due to intolerable symptoms. Current research has revealed that chronic bladder wall inflammation and bladder mucosal denudation are the fundamental pathology for clinical symptoms. After medical treatment or intravesical therapy, urinary inflammatory biomarkers may decrease, and this reduction is associated with clinical symptom improvement. Jing-Si Herbal Tea is a traditional Chinese medicine product that has been shown to have potential effects on autonomic nervous system modulation, immunomodulation, and antioxidant activity. Using Jing-Si-Herbal-Tea may have a therapeutic effect in patients with refractory IC/BPS.
Material and Methods: This study will enroll patients with IC/BPS who are refractory to various conventional treatments (an interstitial cystitis symptom index (ICSI) >12 after cystoscopic hydrodistention, antimuscarinic, and painkiller treatments). These patients plan to receive further intravesical IC therapy, such as intravesical hyaluronic acid (HA) instillation, intravesical botulinum toxin A (Botox) injection, intravesical platelet-rich plasma (PRP) injection, or low-energy shock wave (LESW) therapy. The patients will be investigated for the voiding diary (for frequency and nocturia episodes per day), ICSI, IC problem index (ICPI), Numerical Rating Scale (NRS) of pain, patient perception of bladder condition (PPBC), global response assessment (GRA), maximal flow rate (Qmax), voided volume (Vol), and post-void residual urine (PVR) volume measurement at baseline and after treatment. Urine samples will also be obtained for urinary biomarker determination at baseline and after different therapies. The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing-Si-Herbal-Tea TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also assessed at baseline and at 4, 8, and 12 weeks after treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment. Secondary endpoints include ICSI and ICPI, assessed by self-report of IC/BPS severity and NRS for pain severity; the range of ICSI is 0 to 20 points, and the ICPI total score is 0 to 16 points. Bladder pain was assessed using a self-rated 11-point NRS for severity.
Expected results: The investigators expect IC/BPS patients in the treatment group (combined IC treatment and Jing-Si-Herbal-Tea treatment) to have significantly greater improvement in GRA after 12 weeks of treatment. The investigators also expect that improvement in bladder pain (as measured by NRS) might be the most effective indicator of treatment outcome.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Hualien City, Tajvan, 970
- Hualien Tzu Chi General Hospital, Tzu Chi Medical Foundation
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- This study is expected to select patients with IC (non-ulcer type, Glomerulation >1, interstitial cystitis symptom index (ICSI≧12 points) in the urology outpatient clinic, and use anticholinergic drugs and pain medication treatment. The symptoms have not improved significantly (ICSI≧12). Patients will be asked about their willingness before being selected to confirm that they are willing to accept this clinical trial, and they can be included in this clinical trial after completing the entire course of the treatment test.
Exclusion Criteria:
-
non-IC/BPS patients
-
psychological disease was diagnosed
-
non-NIDDK criteria (Hunner's ulcer type)
-
Under-primary or illiterate respondents
-
patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow up
-
Patients with bladder outlet obstruction on enrollment
-
Patients with post-void residual > 150ml
-
Patients with an uncontrolled confirmed diagnosis of acute urinary tract infection
-
Patients have laboratory abnormalities at screening including:
ALT> 3 x upper limit of normal range AST> 3 x upper limit of normal range Patients have abnormal serum creatinine level >2 x upper limit of normal range
-
Patients who cannot used urinary catheter to treat.
-
Female patients who are pregnant, lactating, or childbearing potential without contraception.
-
Patients with any other serious disease considered by the investigator not in the condition to enter the trial
-
Patients cannot record the voiding diary
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Egészségügyi szolgáltatások kutatása
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Jing Si Herbal Tea liquid packet to treat patients with Interstitial Cystitis/Bladder Pain syndrome
Patients who meet all eligibility requirements for entry into the study will be randomized into combined bladder treatment or only bladder treatment |
The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also investigated at baseline and after treatment, at 4 weeks, 8 weeks, 12 weeks, and 20 weeks after the treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment.
Más nevek:
|
|
Placebo Comparator: Jing Si Herbal Tea liquid packet placebo
Jing Si Herbal Tea liquid packet |
The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also investigated at baseline and after treatment, at 4 weeks, 8 weeks, 12 weeks, and 20 weeks after the treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment.
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Global Response Assessment (GRA) at Week 12
Időkeret: Week 12
|
The Global Response Assessment (GRA) evaluates patient-reported overall changes in bladder symptoms following treatment. Higher scores indicate greater perceived improvement. |
Week 12
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change in Interstitial Cystitis Symptom Index (ICSI)
Időkeret: Baseline and Week 12
|
The Interstitial Cystitis Symptom Index (ICSI) assesses the severity of urinary frequency, urgency, nocturia, and bladder-related pain. Total scores range from 0 to 20, with higher scores indicating more severe symptoms. Change from baseline will be assessed. |
Baseline and Week 12
|
|
Change in Interstitial Cystitis Problem Index (ICPI)
Időkeret: Baseline and Week 12
|
The Interstitial Cystitis Problem Index (ICPI) measures the degree of bother associated with urinary symptoms. Total scores range from 0 to 16, with higher scores indicating greater symptom-related problems. Change from baseline will be assessed. |
Baseline and Week 12
|
|
Change in Bladder Pain Intensity
Időkeret: Baseline and Week 12
|
Bladder pain intensity is assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Change from baseline will be assessed. |
Baseline and Week 12
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Hann Chorng Kuo, M.D., Buddhist Tzu Chi Medical Foundation Hualien Tzu Chi Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- IRB112-149-A
- IRB112-149-A (Egyéb támogatási/finanszírozási szám: Buddhist Tzu Chi General Hospital, Hualien)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .